Literature DB >> 34487636

Life expectancy without a transplant for status 1A liver transplant candidates.

Nicholas L Wood1, Douglas N VanDerwerken1, Elizabeth A King2, Dorry L Segev2,3, Sommer E Gentry1.   

Abstract

Status 1A liver transplant candidates are given the highest medical priority for the allocation of deceased donor livers. Organ Procurement and Transplantation Network (OPTN) policy requires physicians to certify that a candidate has a life expectancy without a transplant of less than 7 days for that candidate to be given status 1A. Additionally, candidates receiving status 1A must have one of six medical conditions listed in policy. Using Scientific Registry of Transplant Recipients data from all prevalent liver transplant candidates from 2010 to 2020, we used a bias-corrected Kaplan-Meier model to calculate the survival of status 1A candidates and to determine their life expectancy without a transplant. We found that status 1A candidates have a life expectancy without a transplant of 24 (95% CI 20-46) days-over three times longer than what policy requires for status 1A designation. We repeated the analysis for subgroups of status 1A candidates based on the medical conditions that grant status 1A. We found that none of these subgroups met the life expectancy requirement. Harmonizing OPTN policy with observed data would sustain the integrity of the allocation process.
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Organ Procurement and Transplantation Network (OPTN); ethics and public policy; law/legislation; liver transplantation/hepatology; mathematical model; organ allocation; organ procurement and allocation; patient survival; statistics; translational research/science

Mesh:

Year:  2021        PMID: 34487636      PMCID: PMC8720063          DOI: 10.1111/ajt.16830

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

1.  Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

Authors:  J M Robins; D M Finkelstein
Journal:  Biometrics       Date:  2000-09       Impact factor: 2.571

2.  Should All Status 1A Patients Be Prioritized Over High MELD Patients? Concept of Risk Stratification in Extremely Ill Liver Transplant Recipients.

Authors:  Mohamed Safwan; Uche Nwagu; Kelly Collins; Marwan Abouljoud; Shunji Nagai
Journal:  Transplantation       Date:  2019-10       Impact factor: 4.939

Review 3.  Big data in organ transplantation: registries and administrative claims.

Authors:  A B Massie; L M Kucirka; L M Kuricka; D L Segev
Journal:  Am J Transplant       Date:  2014-08       Impact factor: 8.086

4.  End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates.

Authors:  Pratima Sharma; Douglas E Schaubel; Qi Gong; Mary Guidinger; Robert M Merion
Journal:  Hepatology       Date:  2011-11-15       Impact factor: 17.425

5.  The Precise Relationship Between Model for End-Stage Liver Disease and Survival Without a Liver Transplant.

Authors:  Douglas N VanDerwerken; Nicholas L Wood; Dorry L Segev; Sommer E Gentry
Journal:  Hepatology       Date:  2021-08       Impact factor: 17.298

6.  Correcting the sex disparity in MELD-Na.

Authors:  Nicholas L Wood; Douglas VanDerwerken; Dorry L Segev; Sommer E Gentry
Journal:  Am J Transplant       Date:  2021-07-12       Impact factor: 9.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.